Journal: Cancers

Article Title: Drug-Induced Resistance and Phenotypic Switch in Triple-Negative Breast Cancer Can Be Controlled via Resolution and Targeting of Individualized Signaling Signatures

doi: 10.3390/cancers13195009

Figure Lengend Snippet: TNBC tissues are represented by different patient-specific signaling signatures, majority of which do not include EGFR. ( A ) Fold changes in expression levels of EGFR and pEGFR in TNBC and non-TNBC tumors are shown. Y1068 and Y1173 are EGFR phosphorylation sites; ( B ) Examples for patient-specific sets of active unbalanced processes are shown. Each sample harbors a set of 1–3 active unbalanced processes (PaSSS), represented schematically by a barcode. In each barcode active unbalanced processes are represented by black or gray squares, inactive white. Negative/positive amplitude denotes how the patients are correlated with respect to a particular process. Suggested PaSSS-based therapies appear below each barcode; ( C ) Heterogeneity index of 3 subgroups, represented by a ratio between the number of distinct PaSSSs and the number of samples in each subset, is shown for the TNBC subset of tissues, the entire set (3467 samples from 11 cancer types) and the subset of non-TNBC samples. (Abbreviations: TNBC—Triple Negative Breast Cancer, PaSSS—Patient-specific signaling signature, EGFR—Epidermal Growth Factor Receptor, VEGFR2—Vascular Endothelial Growth Factor Receptor 2, Her2—Human Epidermal growth factor Receptor 2, Src—Proto-oncogene tyrosine-protein kinase Src).

Article Snippet: The following conjugated antibodies were used: anti-p-EGFR (Y1068) (R&D Systems, Minneapolis, MN, USA, cat. no. IC3570G), anti-p-ERK2 (Thr202/Tyr204) (BioLegend, San Diego, CA, USA, cat. No. 675503), anti-p-S6 (Ser235/236) (BioLegend, cat. no. 608605), and anti-GAPDH (Santa Cruz Biotechnology, Dallas, Texas, USA, cat. no. sc-47724AF594).

Techniques: Expressing, Phospho-proteomics

Journal: Materials Today Bio

Article Title: Porcine decellularized splenic matrix hydrogel-based vesicle sustained-release System: A dual-regulatory biomaterial for accelerated wound healing via angiogenesis and immune remodeling

doi: 10.1016/j.mtbio.2025.102601

Figure Lengend Snippet: pDSMG/SHED-ApoVs promoted skin wound healing in vivo. (A) Photographs of the skin wounds treated with pDSMG/SHED-ApoVs, pDSMG, SHED-ApoVs and PBS. (B) Traces of wound closure of each treatment. (C) Wound healing rate at different time points post-wounding (n = 5). ∗: pDSMG/SHED-ApoVs vs. pDSMG, SHED-ApoVs and PBS groups; # pDSMG vs. SHED-ApoVs and PBS groups; +: SHED-ApoVs vs. PBS groups. (D) H&E staining of tissue sections on day 10. White arrow: regenerated hair follicles and neo-epithelia; black arrow: defect area. (E) Representative Masson staining images of tissue sections on day 10. White arrow: regenerated hair follicles and neo-epithelia; yellow arrow: defect area. Quantification analysis of the width of wounded tissues without hair follicle (F), the number of hair follicles (G), the thickness of the regenerated epithelium (H) and the relative collage area (I) in the wounded tissues on day 10 (n = 5). (J) Representative IF staining images of CD31 + α-SMA + blood vessels in wound regions. CD31: green; α-SMA: red. White arrow: co-localization of CD31 and α-SMA. (K–L) Quantification of the relative area (n = 9) and the number of blood vessels (n = 5) in wound regions. Panels (F–I), (K) and (L) are designated by the same identifier. All data were presented as the means ± SD. Statistical analysis was performed by one-way ANOVA. ns, no significant; ∗ # +, P < 0.05; ∗∗ ## ++, P < 0.01; ∗∗∗ ### +++, P < 0.001; ∗∗∗∗ #### ++++, P < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: The antibodies used were as follows: Anti-CD31 antibody (FAB3628G, R&D Systems, USA; diluted 1:100), Anti-alpha-smooth muscle actin (α-SMA) antibody (ab7817, Abcam, UK; diluted 1:100), Anti-EMCN antibody (14-5851-82, Invitrogen, USA; diluted 1:200), Anti-F4/80 antibody (ab16911, Abcam, UK; diluted 1:200), Anti-iNOS antibody (ab178945, Abcam, UK; diluted 1:200), Anti-IL-6 antibody (12912s, Cell Signaling Technology, USA; diluted 1:200), Anti- Arginase 1(Arg1) antibody (93668s, Cell Signaling Technology, USA; diluted 1:200), Anti-CD4 antibody (11948s, Cell Signaling Technology, USA; diluted 1:200), Anti-CD25 antibody (11948s, Cell Signaling Technology, USA; diluted 1:200), Anti-Foxp3 antibody (22228-1-AP, Proteintech, China; diluted 1:200), Anti-TGF-β antibody (3711s, Cell Signaling Technology, USA; diluted 1:200), Anti-TNF-α, antibody (SC-52746, Santa Cruz Biotechnology, USA; diluted 1:200), Anti-collagen type I alpha 1 chain ( COL1A1 ) antibody (# P02452 , Cell Signaling Technology, USA; diluted 1:200), Alexa Fluor 594 Donkey anti-Mouse secondary antibody (A21203, Invitrogen, USA; diluted 1:200), Alexa Fluor 594 Donkey anti-Rat secondary antibody (A21209, Invitrogen, USA; diluted 1:200), Alexa Fluor 594 Donkey anti-Rabbit secondary antibody (A21207, Invitrogen, USA; diluted 1:200), Alexa Fluor 488 Donkey anti-Rabbit secondary antibody (A21206, Invitrogen, USA; diluted 1:200)

Techniques: In Vivo, Staining

Journal: Materials Today Bio

Article Title: Porcine decellularized splenic matrix hydrogel-based vesicle sustained-release System: A dual-regulatory biomaterial for accelerated wound healing via angiogenesis and immune remodeling

doi: 10.1016/j.mtbio.2025.102601

Figure Lengend Snippet: pDSMG/SHED-ApoVs promoted re-epithelialization and angiogenesis at early phase of wound healing. (A) Photographs of treated wounds at 4 days after surgery and quantification of the wound healing rate (n = 5). (B) H&E and Masson staining of wound regions and quantification of the length of neo-epithelia on day 4 (n = 5). Yellow line: neo-epithelia; Black line: the edge of wound area. (C) Schematic diagram of the cell scratch assay process. (D) Representative images of scratch assay of HaCaT pre-incubated with different groups. (E) Quantification of the migration rate of HaCaT (n = 9). (F) Representative IF staining images of CD31 + EMCN + blood vessels in wound regions. CD31: green; EMCN: red (G) Quantification of the relative area of blood vessels (n = 9) and the numbers of blood vessels in wounded areas (n = 5). All data were presented as the means ± SD. Statistical analysis was performed by one-way ANOVA. ns, no significant; ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗, P < 0.001; ∗∗∗∗, P < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: The antibodies used were as follows: Anti-CD31 antibody (FAB3628G, R&D Systems, USA; diluted 1:100), Anti-alpha-smooth muscle actin (α-SMA) antibody (ab7817, Abcam, UK; diluted 1:100), Anti-EMCN antibody (14-5851-82, Invitrogen, USA; diluted 1:200), Anti-F4/80 antibody (ab16911, Abcam, UK; diluted 1:200), Anti-iNOS antibody (ab178945, Abcam, UK; diluted 1:200), Anti-IL-6 antibody (12912s, Cell Signaling Technology, USA; diluted 1:200), Anti- Arginase 1(Arg1) antibody (93668s, Cell Signaling Technology, USA; diluted 1:200), Anti-CD4 antibody (11948s, Cell Signaling Technology, USA; diluted 1:200), Anti-CD25 antibody (11948s, Cell Signaling Technology, USA; diluted 1:200), Anti-Foxp3 antibody (22228-1-AP, Proteintech, China; diluted 1:200), Anti-TGF-β antibody (3711s, Cell Signaling Technology, USA; diluted 1:200), Anti-TNF-α, antibody (SC-52746, Santa Cruz Biotechnology, USA; diluted 1:200), Anti-collagen type I alpha 1 chain ( COL1A1 ) antibody (# P02452 , Cell Signaling Technology, USA; diluted 1:200), Alexa Fluor 594 Donkey anti-Mouse secondary antibody (A21203, Invitrogen, USA; diluted 1:200), Alexa Fluor 594 Donkey anti-Rat secondary antibody (A21209, Invitrogen, USA; diluted 1:200), Alexa Fluor 594 Donkey anti-Rabbit secondary antibody (A21207, Invitrogen, USA; diluted 1:200), Alexa Fluor 488 Donkey anti-Rabbit secondary antibody (A21206, Invitrogen, USA; diluted 1:200)

Techniques: Staining, Wound Healing Assay, Incubation, Migration

Journal: Materials Today Bio

Article Title: Porcine decellularized splenic matrix hydrogel-based vesicle sustained-release System: A dual-regulatory biomaterial for accelerated wound healing via angiogenesis and immune remodeling

doi: 10.1016/j.mtbio.2025.102601

Figure Lengend Snippet: pDSMG/ApoVs accelerated wound healing in proliferative phase. (A) Photographs of treated wounds and quantification of the wound healing rate at 7 days post-injury (n = 5). (B) H&E staining of wound regions on day 7 and quantification of the length of neo-epithelia (n = 5). Black arrow: regenerated hair follicles; Red arrow: newly formed vesicles; Yellow line: stratum basale. (C) H&E staining results of the regions marked in the box above. The left images: the edge of the skin wound area. The right images: the center of the skin wound area. (D) Masson staining of wound regions. The left images: the edge of the skin wound area. The right images: the center of the skin wound area. (E) Quantification of the number of hair follicles, the epithelial thickness, the width of wounded tissues without hair follicles and the relative regenerative collagen area in wound regions on day 7 (n = 5). (F) Representative IF staining images of CD31 (green) and α-SMA (red) staining in wound regions on day 4. (G) Representative IF staining images of CD31 (green) and α-SMA (red) staining in wound regions on day 7. (H) Quantification of the number of CD31 + α-SMA+blood vessels in wound regions on day 4 (n = 5). (I) Quantification of the number of CD31 + α-SMA+blood vessels in wound regions on day 7 (n = 5). (J) Numbers of blood vessels at different time points post-wounding (n = 5). ∗: pDSMG/SHED-ApoVs vs. pDSMG, SHED-ApoVs and PBS groups; # pDSMG vs. SHED-ApoVs and PBS groups; +: SHED-ApoVs vs. PBS groups. Panels (E) and (H–J) are designated by the same identifier. All data were presented as the means ± SD. Statistical analysis was performed by one-way ANOVA. ns, no significant; ∗ # +, P < 0.05; ∗∗ ## ++, P < 0.01; ∗∗∗ ### +++, P < 0.001; ∗∗∗∗ #### ++++, P < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

Article Snippet: The antibodies used were as follows: Anti-CD31 antibody (FAB3628G, R&D Systems, USA; diluted 1:100), Anti-alpha-smooth muscle actin (α-SMA) antibody (ab7817, Abcam, UK; diluted 1:100), Anti-EMCN antibody (14-5851-82, Invitrogen, USA; diluted 1:200), Anti-F4/80 antibody (ab16911, Abcam, UK; diluted 1:200), Anti-iNOS antibody (ab178945, Abcam, UK; diluted 1:200), Anti-IL-6 antibody (12912s, Cell Signaling Technology, USA; diluted 1:200), Anti- Arginase 1(Arg1) antibody (93668s, Cell Signaling Technology, USA; diluted 1:200), Anti-CD4 antibody (11948s, Cell Signaling Technology, USA; diluted 1:200), Anti-CD25 antibody (11948s, Cell Signaling Technology, USA; diluted 1:200), Anti-Foxp3 antibody (22228-1-AP, Proteintech, China; diluted 1:200), Anti-TGF-β antibody (3711s, Cell Signaling Technology, USA; diluted 1:200), Anti-TNF-α, antibody (SC-52746, Santa Cruz Biotechnology, USA; diluted 1:200), Anti-collagen type I alpha 1 chain ( COL1A1 ) antibody (# P02452 , Cell Signaling Technology, USA; diluted 1:200), Alexa Fluor 594 Donkey anti-Mouse secondary antibody (A21203, Invitrogen, USA; diluted 1:200), Alexa Fluor 594 Donkey anti-Rat secondary antibody (A21209, Invitrogen, USA; diluted 1:200), Alexa Fluor 594 Donkey anti-Rabbit secondary antibody (A21207, Invitrogen, USA; diluted 1:200), Alexa Fluor 488 Donkey anti-Rabbit secondary antibody (A21206, Invitrogen, USA; diluted 1:200)

Techniques: Staining